Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management

CX Ma, XN Ma, CH Guan, YD Li, D Mauricio… - Cardiovascular …, 2022 - Springer
Cardiovascular diseases (CVDs) are the main cause of death among patients with type 2
diabetes mellitus (T2DM), particularly in low-and middle-income countries. To effectively …

[HTML][HTML] Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events

E Raschi, M Casula, AFG Cicero, A Corsini… - Pharmacology & …, 2023 - Elsevier
The pharmacological treatment of dyslipidemia, a major modifiable risk factor for develo**
atherosclerotic cardiovascular disease (ASCVD), remains a debated and controversial …

Treatment gaps in the implementation of LDL cholesterol control among high-and very high-risk patients in Europe between 2020 and 2021: the multinational …

KK Ray, I Haq, A Bilitou, MC Manu… - The Lancet Regional …, 2023 - thelancet.com
Background European data pre-2019 suggest statin monotherapy is the most common
approach to lipid management for preventing cardiovascular (CV) events, resulting in only …

[HTML][HTML] PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021

M Banach, P Burchardt, K Chlebus… - Archives of Medical …, 2021 - ncbi.nlm.nih.gov
Moreover, over the last few years the approach to treatment of patients with a high
cardiovascular risk has totally changed from treatment aimed at a specific risk factor (ie …

Intensive statin therapy versus upfront combination therapy of statin and ezetimibe in patients with acute coronary syndrome: a propensity score matching analysis …

J Lewek, J Niedziela, P Desperak… - Journal of the …, 2023 - Am Heart Assoc
Background We aimed to compare statin monotherapy and upfront combination therapy of
statin and ezetimibe in patients with acute coronary syndromes (ACSs). Methods and …

[HTML][HTML] A look to the past–what has had the biggest impact on lipids in the last four decades? A personal perspective

M Banach, S Surma - Archives of Medical Science: AMS, 2023 - ncbi.nlm.nih.gov
We live in interesting times, when we finally have the possibility of effective treatment of
patients with lipid disorders, and in fact with numerous effective drugs available, it should be …

Reducing residual cardiovascular risk in Europe: therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid

MJ Chapman, JL Zamorano, KG Parhofer - Pharmacology & therapeutics, 2022 - Elsevier
Atherosclerotic cardiovascular disease (ASCVD) and its atherothrombotic complications
impose a substantial disease burden in Europe, representing a cost of€ 210 billion per year …

Causal associations between Gut Microbiota and different types of Dyslipidemia: a two-sample mendelian randomization study

X Zhou, P Lian, H Liu, Y Wang, M Zhou, Z Feng - Nutrients, 2023 - mdpi.com
The determination of a causal association between gut microbiota and a range of
dyslipidemia remains uncertain. To clarify these associations, we employed a two-sample …

[HTML][HTML] 2022: the year in cardiovascular disease–the year of upfront lipid lowering combination therapy

M Banach, Z Reiner, AFG Cicero… - Archives of Medical …, 2022 - ncbi.nlm.nih.gov
Recent data clearly show that we are extremely ineffective in the use of lipid-lowering
therapy (LLT). Furthermore, the problem seems to be the most serious in the group of …

New therapies for primary hyperlipidemia

CA Aguilar-Salinas, RA Gómez-Díaz… - The Journal of Clinical …, 2022 - academic.oup.com
Primary hyperlipidemias include a heterogeneous set of monogenic and polygenic
conditions characterized by a strong family aggregation, severe forms of …